Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Emergent BioSolutions
ClinicalTrials.gov Identifier:
NCT01491607
First received: December 12, 2011
Last updated: June 19, 2012
Last verified: June 2012
  Purpose

The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax.

This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years.

The duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.


Condition Intervention Phase
Anthrax
Biological: BioThrax
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Resource links provided by NLM:


Further study details as provided by Emergent BioSolutions:

Primary Outcome Measures:
  • Immunogenicity as measured by anti-protective antigen (PA) antibody responses using the toxin neutralization antibody assay [ Time Frame: 100 days ] [ Designated as safety issue: No ]
    Proportion of subjects acheiving a threshold response.


Secondary Outcome Measures:
  • Immunogenicity, as defined by a predicted vaccine efficacy at defined timepoints. [ Time Frame: 100 days ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: November 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BioThrax (0.5 mL, on days 0, 14, and 28) Biological: BioThrax
BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
Other Name: Anthrax Vaccine Adsorbed (AVA)

Detailed Description:

BioThrax® (also called Anthrax Vaccine Adsorbed or AVA) is the only FDA-licensed vaccine for the prevention of anthrax infection. This study will evaluate the immunogenicity of the vaccine using a post-exposure vaccination schedule. Correlations will be drawn to immunogenicity and survival data from animal models to demonstrate that BioThrax® can elicit a protective immune response for PEP.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be between 18 and 65 years of age, inclusive, at the time of enrollment.
  • Be in good health as determined by the investigator from medical history and a physical examination.
  • If a pre-menopausal female, must be using acceptable methods of birth control.
  • Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
  • Be willing and able to return for all visits and blood collections for the duration of the study.
  • Have read, understood and signed an informed consent form.

Exclusion Criteria:

  • Prior immunization with anthrax vaccine or known exposure to anthrax organisms.
  • Intend to enlist in the military during the study.
  • Have a known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex.
  • Plan to receive experimental products at any time during the study.
  • Have received a live vaccine in the 30 days before study entry.
  • Plan to receive a live vaccine at any time during the study.
  • Have ongoing drug abuse/dependence (including alcohol) issues and/or test positive in a urine drug screen for amphetamines, barbiturates, cocaine or opiates;
  • Have received immunosuppressive therapy (including systemic steroids) within 3 months prior to study entry.
  • Have a condition known to produce or be associated with immunosuppression.
  • Have received cytotoxic therapy in the previous 5 years.
  • A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01491607

Locations
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33143
United States, New York
Rochester Clinical Research
Rochester, New York, United States, 14609
United States, South Carolina
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States, 29464
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Emergent BioSolutions
Investigators
Principal Investigator: Robert Hopkins, MD, MPH, TM Emergent BioSolutions Inc.
  More Information

No publications provided

Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT01491607     History of Changes
Other Study ID Numbers: EBS.AVA.006, HHSO100200700037C
Study First Received: December 12, 2011
Last Updated: June 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Emergent BioSolutions:
post-exposure prophylaxis
toxin neutralization assay

Additional relevant MeSH terms:
Anthrax
Bacillaceae Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on June 18, 2013